Literature DB >> 8971694

Brain lysosomal hydrolases in neuronal ceroid-lipofuscinoses.

V V Prasad1, R K Pullarkat.   

Abstract

Although the neuronal ceroid-lipofuscinoses (NCLs) are often referred to as lysosomal storage disorders, information on brain lysosomal hydrolases in NCLs is not available. We have determined the specific activities of several acid hydrolases in postmortem brain gray matter of infantile (INCL), late infantile (LINCL), juvenile (JNCL), and adult (ANCL) forms of NCL, patients affected with other neurological disorders (ON), and normal controls. The specific activities of beta-hexosaminidase A and B were significantly high in JNCL gray matter, whereas in LINCL, the increase is significant only in beta-hexosaminidase compared to the controls. A significant increase in the activities of alpha-mannosidase, beta-glucuronidase, and acid phosphatase was also observed in LINCL and JNCL patients compared to the control values. beta-galactosidase activity was also found to be elevated in JNCL brains over the controls. In contrast, activities of beta-glucosidase and sialidase appeared to be lowered in INCL and LINCL. On the other hand, alpha-fucosidase, beta-mannosidase, and sulfatase were unaffected in NCLs brains. Thus, the present data indicate NCLs related abnormalities in some of the acid hydrolases in brain gray matter, which are primarily glycoproteins of lysosomal origin. These data in conjuction with the reported association of sphingolipid activator proteins (SAP) A and D and lysosomal glycoproteins with NCL storage bodies imply abberations in the glycoconjugate metabolism and lysosomal function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971694     DOI: 10.1007/BF02815000

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  7 in total

1.  A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration.

Authors:  J Tyynelä; I Sohar; D E Sleat; R M Gin; R J Donnelly; M Baumann; M Haltia; P Lobel
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Palmitoyl-protein thioesterase 1 deficiency in Drosophila melanogaster causes accumulation of abnormal storage material and reduced life span.

Authors:  Anthony J Hickey; Heather L Chotkowski; Navjot Singh; Jeffrey G Ault; Christopher A Korey; Marcy E MacDonald; Robert L Glaser
Journal:  Genetics       Date:  2006-02-01       Impact factor: 4.562

3.  A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells.

Authors:  Amanda L Getty; Jared W Benedict; David A Pearce
Journal:  Exp Cell Res       Date:  2010-09-17       Impact factor: 3.905

4.  Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration.

Authors:  Dagmar Kasper; Rosa Planells-Cases; Jens C Fuhrmann; Olaf Scheel; Oliver Zeitz; Klaus Ruether; Anja Schmitt; Mallorie Poët; Robert Steinfeld; Michaela Schweizer; Uwe Kornak; Thomas J Jentsch
Journal:  EMBO J       Date:  2005-02-10       Impact factor: 11.598

5.  Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses.

Authors:  D E Sleat; I Sohar; P S Pullarkat; P Lobel; R K Pullarkat
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

6.  Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner.

Authors:  Kristina Oresic; Britta Mueller; Domenico Tortorella
Journal:  Biosci Rep       Date:  2009-06       Impact factor: 3.840

7.  A hereditary spastic paraplegia mouse model supports a role of ZFYVE26/SPASTIZIN for the endolysosomal system.

Authors:  Mukhran Khundadze; Katrin Kollmann; Nicole Koch; Christoph Biskup; Sandor Nietzsche; Geraldine Zimmer; J Christopher Hennings; Antje K Huebner; Judit Symmank; Amir Jahic; Elena I Ilina; Kathrin Karle; Ludger Schöls; Michael Kessels; Thomas Braulke; Britta Qualmann; Ingo Kurth; Christian Beetz; Christian A Hübner
Journal:  PLoS Genet       Date:  2013-12-19       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.